Table 118, Probability of exacerbations in the model, chronic antibiotic treatment - Cystic Fibrosis

Warning: The NCBI web site requires JavaScript to function. more...

Comparison	Baseline probability	OR	Treatment related probability^a
First cycle (28 days)
Nebulised tobramycin versus placebo	6%^b	3.00	16%
Tobramycin dry powder versus placebo		1.10^b	6%^c
Nebulised aztreonam lysine versus placebo		0.30	2%
Subsequent cycles (24 weeks)
Nebulised tobramycin versus placebo	40%^d	0.88	37%
Tobramycin dry powder versus placebo		1.01	40%
Nebulised aztreonam lysine versus placebo		0.40	21%
Combination^e versus placebo		0.67	31%

(a): Calculated by transforming the baseline probability into an odds and transforming back into a probability
(b): 6% reported for placebo by Ramsey 1993 over 28 days and 14% by Retsch-Bogart 2009 over 42 days
(c): Long-term assumed to equal short-term in the absence of data, also adjusted from a 6-month probability to a 1-month probability
(d): 40% reported for placebo by Chuchalin 2007 over 24 weeks
(e): Nebulised aztreonam plus nebulised tobramycin

Cystic Fibrosis: Diagnosis and management.

NICE Guideline, No. 78.

National Guideline Alliance (UK).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.